Fludarabine
Progressive Hairy Cell Leukemia, Initial Treatment
Kite, A Gilead CompanySmall moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Progressive Hairy Cell Leukemia, Initial Treatment cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Kite, A Gilead Company | Phase 2 | BB |
Cediranib Alexey Danilov, MD | Phase 1/2 | B |
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Acerta Pharma BV | Phase 1/2 | B |
cc-5013 Joseph Tuscano | Phase 1/2 | B |
Obinutuzumab Joseph Tuscano | Phase 1/2 | B |
View all 43 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →